Growth Metrics

Biogen (BIIB) Capital Expenditures (2016 - 2026)

Biogen has reported Capital Expenditures over the past 18 years, most recently at $51.2 million for Q1 2026.

  • For Q1 2026, Capital Expenditures rose 38.01% year-over-year to $51.2 million; the TTM value through Mar 2026 reached $167.9 million, up 15.87%, while the annual FY2025 figure was $153.8 million, 0.07% changed from the prior year.
  • Capital Expenditures for Q1 2026 was $51.2 million at Biogen, up from $43.9 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $86.4 million in Q4 2022 and troughed at $26.6 million in Q2 2025.
  • A 5-year average of $51.5 million and a median of $46.2 million in 2025 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: surged 92.41% in 2023 and later tumbled 52.83% in 2024.
  • Year by year, Capital Expenditures stood at $86.4 million in 2022, then dropped by 24.54% to $65.2 million in 2023, then tumbled by 39.72% to $39.3 million in 2024, then grew by 11.7% to $43.9 million in 2025, then grew by 16.63% to $51.2 million in 2026.
  • Business Quant data shows Capital Expenditures for BIIB at $51.2 million in Q1 2026, $43.9 million in Q4 2025, and $46.2 million in Q3 2025.